Список литературы 

1.     Шмидт Е.В. Стеноз и тромбоз сонных артерий инарушения мозгового кровообращения. М.: Мед-гиз. 1963; 320.

2.     Инсульт. Принципы диагностики, лечения и профилактики. Под ред. Н.В. Верещагина, М.А. Пирадова, М.А. Евзельмана. М.: Фаворъ. 2002; 208.

3.     Гусев Е.И. Проблема инсульта в России. Журнал Ин-та неврологии и психиатрии им. С.С. Корсакова, Прил. «Инсульт». 2003; 9: 3-7.

4.     Верещагин Н.В., Джибладзе Д.Н., Бархатов Д.Ю. Оценка цереброваскулярного резерва при атеросклеротическом поражении сонных артерий. Журнал Ин-та неврологии и психиатрии им. С.С. Корсакова, Прил. «Инсульт». 2003; 9: 7-13.

5.     Патология сонных артерий и проблема ишемического инсульта (клинические, ультразвуковые и гемодинамические аспекты). Под ред. Д.Н. Джибладзе. М.: Медицина. 2002; 226.

6.     Куперберг Е.Б. Клиническая допплерография окклюзирующих поражений артерий мозга и конечностей. Ангиология и сосудистая хирургия. 1997; 2: 63-87.

7.     Фонякин А.В., Суслина З.А., Гераскина Л.А. Кардиологическая диагностика при ишемическом инсульте. С.-Пб: Инкарт. 2005; 224.

8.     Davis WD., Hart R.G. Cardiogenic stroke in the eldery. Clin. Geriatr. Med. 1991; 7: 429-442.

9.     Szocs K., Lassegue В., Sorescu D. et al. Upregulation of Nox-based NAD oxidases in restenosis after carotid in jury. Arterioscler. Thromb. Vase. Biol. 2002; 22: 21-27

10.   Basic identification criteria of Doppler microembolic signals. Consensus Committee of the Ninth International Cerebral Hemodynamics Symposium. 1995.

11.   Кузнецов А.Л., Фонякин А.В., Суслина З.А. Транскраниальное допплеровское мониторирование средних мозговых артерий в оценке риска повторной церебральной эмболии в разные стадии кардиоэмболического инсульта. Невр. журн. 2002; 3: 10-13.

12.   Фонякин А.В., Гераскина Л. А. Современные задачи кардионеврологии. Невр. журн. 2002; 2: 18-25.

13.   Крашенинникова Н.В. Клинико-эхокардиографические характеристики лиц с готовностью к апрадоксальной эмболии. Автореф. дисс. канд. мед. наук. С.-Пб. 2006; 22.

14.   Wiebers D.O., Agmon Y, Khandheria B.K. et al. Frequency of Atrial Septal Aneurysms in Patients Wit Cerebral Ischemic Events. Presented in part at the 47^th Annual Scientific Session of the American College of Cardiology. Atlanta. G. 1998. Circulation. 1999; 99: 1942-1944.

15.   Онищенко Е.Ф. Открытое овальное окно и инсульт в клинической практике. С.-Пб: ЭЛБИ-СПб. 2005; 191. 16.    Ицкович И.Э., Онищенко Е.Ф., Ильин А.С, Крашенинникова Н.В. Дифференциально-диагностические возможности комплексного лучевого исследования. Вестник рентгенологии и радиологии. 1995; 6: 45-47

17.   Hung J., Landzberg M.J., Jenkins KJ. et al. Closure of patent foramen ovale for paradoxical emboli: inter mediate-term risk of recurrent neurological events following transcatheter device placement./ Am. Coll. Cardiol. 2000; 35: 1311-1316.

18.   Lock J.E., Rome J.J., Davis R. et al. Transcatheter closure of atrial septal defects. Experimental studies. Circulation. 2000; 79: 1091-1099.

19.   Wolf P. A., Mitchell J.B., Baker C.S. Impact of atrial fib rillation on mortality, stroke and medical costs. Arch. Intern. Med. 1998; 158 (3): 229-234.

20.   Булгак А.Г. Риск тромбообразования у больных ИБС с мерцательной аритмией - влияние степени митральной регургитации. Актуальные проблемы теории, практики медицины, подготовки научных и профессиональных кадров. Сб. научных трудов в 2 томах. Т. 1. Минск: МЕТ. 2002; 170.

21.   Mugge A., Daniel WG, Haverich A., Lichtlen PR. Diagnosis of nonfective mass lesions by two-demensional echocardiography. Comparison of the transthoracic and transesophageal approaches. Circulation. 1991; 81 (1): 70-78.

22.   Fuster V, Ryden L.E., Asinger R.W et al. Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Eur. Heart J. 2001; 22: 1852-1923.

23.   Baubion N. Value of transesophageal echocardiography in the therapeutic management of non-valvular atrial fibrillation. Arch. Mai. Coeur. Vaiss. 1996; 89 (10): 1291-1295.

24.   Cabanes L. How to search for a cardiac cause of an arterial embolism./ Mai. Vase. 1993; 18(4): 340-344.

25.   Antonielli E., Pizzuti A., Gandolfo N. Transesophageal echocardiography in patients with atrial fibrillation, candidates for cardioversion: usefulness and limitations. G. Ital. Cardiol. 1995; 25 (5): 543-552.).

26.   Mugge A., Daniel WG., Frank G. Echocardiography in infective endocarditis reassessment of prognostic implications of vegetation size by the transthoracic and transesophagel approach. J. Am. Coll. Cardiol. 1989; 14:631-638.

27.   Khan G.N., Dairywala I.Т., Liu Z. et al. Three-Dimensional Echocardiography of Left Atrial Appendage Thrombus./ Cardiovascular Ultrasound & Allied Techniques. 2001; 18 (2): 163-166.

28.   Stollberger C, Finsterer J., Ernst G., Schneider B. Is left atrial appendage occlusion useful for prevention of stroke or embolism in atrial fibrillation? Zeitschrift J. Kardiologie. 2002; 95 (5): 376-379.

29.   Hanna I.R., Kolm P., Martin R., et al. Atrial structure and function after percutaneous lef atrial appendage transcatheter occlusion (PLAATO): Six-month echo-cardiographic follow-up. J. Am. Coll. Cardiol. 2004; 43: 1868-1872.

30.   Schneider В., Stollberger K. et al. Surgical closure of the Left Atrial Appendage - A Beneficial Procedure? Cardiology. 2005; 10: 104-132.

31.   Blackshear J.L., Odell J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann. Thorac. Surg. 1996; 61: 755-759.

Список литературы 

1.    World   Health   Organisation.   The   World Health Report 2000. Health systems: improving performance.  Geneva: World Health Organisation. 2000.

2.    Russian National Society for Atherothrombosis.  There is no atherothrombosis without atherosclerosis. Atherothrombosis bulletin. 2004;1:2.

3.    McNicol A., Israels S.J. Platelets and anti-platelet therapy. J. Pharmacol.  Sci.  2003;  93  (4):381-396.

4.    Patrono C. et al. Expert consensus document on the use of antiplatelet agents. Тhe task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur. Heart. J. 2004; 25 (2): 166-181.

5.    Smith S.C.Jr. et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) – executive summary. А report of the American College of Cardiology / American Heart Association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions.   Circulation.  2001;   103   (24):3019-3041.

 6.   Storey R.F. The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets.2001; 12 (4): 197-209.

7.    Bertrand M.E. et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation   versus   Aspirin   and   Ticlopidine (FANTASTIC) study. Circulation. 1998; 98 (16): 1597-1603.

8.    Schomig A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl.J. Med. 1996; 334 (17): 1084-1089.

9.    Urban P. et al. Randomized evaluation of anti-coagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 1998; 98 (20): 2126-2132.

10.  Leon M.B. et al. A clinical trial comparing three  antithrombotic-drug  regimens  after coronary-artery stenting.  Stent Anticoagulation Restenosis Study Investigators. N. Engl.J. Med. 1998; 339 (23): 1665-1671.

11.  Bertrand M.E. et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Тhe Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS).    Circulation.    2000;    102    (6):        18.624-629.

12.  Elias M., Reichman N., Flatau E. Bone marrow aplasia associated with ticlopidine therapy. Am.J. Hematol. 1993; 44 (4): 289-290.

13.  Montalescot G. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON - TIMI 38).Double-blind, randomized controlled trial.Lancet. 2009; 373 (9665): 723-731.

14.  Sugidachi A. et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br.J. Pharmacol. 2000; 129 (7): 1439-1446.

15.  Brandt J.T. et al. Superior responder rate for inhibition of platelet aggregation with a 60 mg loading dose of prasugrel (CS-747, LY640315) compared with a 300 mg loading dose of clopidogrel. J. Am. Col. Cardiol. 2005; 45: 87A.Abstract 863-865.

16.  Asai E et al. A comparison of prasugrel (CS-747, LY640315) with clopidogrel on platelet function in healthy male volunteers. J. Am.Col. Cardiol. 2005; 45: 87A. Abstract 865-868.

17.  Wiviott S.D. et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO - TIMI 26) trial. Circulation. 2005; 111 (25): 3366-3373.

18.    Wiviott S.D. et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation. 2007; 116 (25): 2923-2932.

19.    Wiviott S.D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl.J. Med. 2007; 357 (20): 2001-2015.

20.    Wiviott S.D. et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in TRITON - TIMI 38. Circulation. 2008; 118 (16): 1626-1630.

21.    Wiviott S.D. et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON - TIMI 38 trial. А subanalysis of a randomised trial. Lancet. 2008; 371 (9621): 1353-1363.

22.    Murphy S.A. et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON - TIMI 38 trial. Eur. Heart. J. 2008; 29 (20): 2473-2479.

Список литературы 

1.      Giroud M., Gras P., Milan С. et al. Mortality of cerebral infarction with auricular )Rev. Epidemiol. Sante Publique. 1993; 41 (1): 90-96.

2.      Novello P., Ajmar G., Bianchini D. et al. Ische-mic stroke and atrial fibrillation. Ital.J. Neurol. Sci. 1993; 14 (7): 571-576.

3.      Mattle H. Long-Term Outcome after stroke due to atrial fibrilation.    Cerebrovascular. Dis.2003; 6: 3-8.

4.      Feinberg W., Blackshear J., Laupacis А. et al. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch.  Intern.  Med.   1995;   155:469-473.

5.      Go A., Hylek E., Phillips K. et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation. JAMA. 2001;285:2370-2375.

6.      Hart R.,  Halperin J. Atrial fibrillation and Stroke.  Concepts and controversies.  Stroke.2001;32: 803-808.

7.      Wolf P., Abbott R., Kannel W. Atrial fibrillation as an independent risk factor for stroke.Stroke. 1991; 22: 983-988. http://www. euro. who. int/document/e8 9242r.pdf

8.    Парфенов В.А. Лечение инсульта.  РМЖ. 2000; 8 (10): 426-432.

9.      Goldstein L., Adams С, Becker К. et al. Primary prevention of Ischemic Stroke. Circulation. 2001;103: 163-182.

10.    Кушаковский М.С. Аритмии сердца. С-Пб.:Фолиант. 2007; 672.

11.    Джанашия П.Х., Назаренко В.А., Николенко С.А. Мерцательная аритмия: современные концепции и тактика лечения. М.: Рос.гос. мед. ун-т. 2001; 107.

12.    Fuster  V.,   Ryden   L.,   Cannom   D.   et   al. ACC/AHA/ESC  2006  Guidelines for the management of patients with   atrial fibrillation - executive summary.  Circulation. 2006;114:700-752.

13.    Бураковский В.И., Бокерия Л.А. Руковод   ство по сердечно-сосудистой хирургии. М.:Медицина. 1989; 49.

14.    Sievert H., Lech M., Treples Т. et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation. Circulation. 2002; 105:1887-1889.

15.    Kannel W., Wolf P., Benjamin E. et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am.J. Cardiol. 1998; 82: 2-9.

16.    Fihn S., McDommel M., Matin D. et al. Riskfactors fоr complications of chronic anticoagulation: a multicenter study. Warfarin optimized outpatient follow-up study groop. Ann.Intern. Med. 1993; 118 (7): 511-520.

17.    Gorter J. For the stroke prevention in reversible  ischemia trial  (SPIRIT)  and European atrial fibrillation trial (EAFT) study groups.Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors.Neurology. 1999; 53; 1319-1327.

18.    Madden J.  Resection of the left auricular appendix. JAMA. 1948; 140: 769-772.

19.    Bailey C., Olsen A., Keown K. et al. Commisurotomy for mitral stenosis: technique for prevention of cerebral complications. JAMA. 1952;149: 1085-1091.

20.  Healey J., Crystal E., Lamy A. et. al. Left atrial appendage occlusion study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke.Am. Heart. J. 2005; 150 (2): 288-293.

21.  Bonow R., Carabello B., de Leon A. et al. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the american college of cardiology. J. Am. Coll. Cardiol. 1998; 32: 1486-1582.

22.  OdellJ., Joseph L., Blackshear J. et. al. Toracoscopic obliteration of   the left atrial appendage: potential for stroke reduction? Ann. Thorac. Surg. 1996: 61: 565-569.

23.  Blackshear J., Jonson D., OdellJ. et. al. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation.J. Am. Coll. Cardiol. 2003; 42:1249-1252.

24.  Ostermayer S.,  Reisman M.,  Kramer P.  Et al.    Percutaneous    left    atrial    appendage transcatheter occlusion  (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation. J. Am. Coll.Cardiol. 2005, 46: 9-14.

25.  Nakai T, Lesh M., Gesterfeld E. et al. Percutaneous  left atrial appendage  occlusion (PLAATO) for preventing cardioembolism.Circulation. 2002; 105: 2217-2222.

27.  Hanna I., Kolm P., Martin R. et al. Left atrial structure and function after percutaneous left atrial   appendage   transcatheter   occlusion (PLAATO). J.  Am.   Coll.   Cardiol.  2004;  43:1868- 872.

28.  Onalan O., Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke.2007; 38: 624-630.

29.  Eilen D., El-Chami M., Grow P. et al. Clinical outcomes three years after PLAATO implantation. Abstracts. Ann. Resear. Day. 2007; 15 (21).

30.  Blackshear J., OdellJ. et al. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann.  Thorac.Surg. 1996; 61: 755-759.

31.  Davis   W.,    Hart   R.    Cardiogenic   stroke in the eldery.   Clin.   Geriatr. Med.  1991;  7:429-442.

32.  Stöllberger C.,  Schneider B.,  Finsterer J.Serious complications from dislocation of a WATCHMAN left atrial appendage occluder.J. Cardiovasc. Electrophysiol. 2007; 18: 880-881.

 33. Sick P.,  Schuler G.,  Hauptmann K.  et.  al. Initial   worldwide    experience    with    the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J. Am.Coll. Cardiol. 2007; 49: 1490-1495.

34.  Block P. Watching the WATCHMAN. J. Am.Coll. Cardiol. 2007; 49: 1496-1497.

35.  Meier B.,  Palacios I., Windecker S.  et al.Transcatheter left atrial appendage occlusionwith Amplatzer devices to obviate anticoa-gulation in patients with atrial fibrillation. Cathet. and Cardiovasc. Interv. 2003; 60: 417-422.

36. Gu X., Qian Z., Zhao С et al. Preclinical evaluation of the Amplatzer cardiac Plug to occlude the left atrial appendage in a canine model. Abstracts. Cong. & Struct. Intervent. 2008; 97.

Список литературы

1.     Derkx F.H., Schalekamp M.A. Renal artery   stenosis and hypertention. Lancet. 1994; 344:237-239.

2.     White C.J. Cateter-based therapy for atherosclerotic  renal artery stenosis.   Circulation.2006; 113: 1464-1473.

3.     SafianR.D.,TextorS.C. Renal artery stenosis. N. Engl.J. Med. 2001; 344: 431-442.

4.     White C.J. et al. Renal artery stent placement: utility in lesions difficult to treat with balloon angioplasty.J. Am. Coll. Cardiol. 1997;30:1445-1450.

5.     Murphy T.P., Soares G., Kim M. Increase of utilization   of percutaneous   renal  artery interventions. Am.J. of Roentgenol. 2004; 183:561-568.

6.     Baumgartner I. et al. Stent placement in ostial and nonostial atherosclerotic renal arterial stenoses. A prospective follow-up study.Radiology. 2000; 216: 498-505.

7.     Van de Ven P.J. et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease:  a randomised trial. Lancet. 1999; 353: 282-286.

8.     ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial   disease.    Circulation.   2006;   113: 463-654.

9.     DanduN., Jaffery Z., Collins T.J. Использование метода киссинг-стентирования при стенозах удвоенных почечных артерий. Межд.   ж. интервенц. кардиоангиологии. 2009; 17: 41-42.

10.    Micari A.,  Falzone A.,  Pernice V.  Kissing stent approach for a case of dual stenotic renal artery ostia.J. Сardiovasc. Мed. 2008; 9: 211-212.

11.    Thomas M. et al. Percutaneos coronary intervention for bifurcation desease. Eurointerven-tion. 2006; 2: 149-153.

12.      Morice M.C. et al. Influence of technical stra tegies on the outcome of coronary bifurcation stenting. Eurointervention. 2005; 1: 31-37.

13.      Aliabadi D. et al. Incidence and angio graphic predictors of side branch occlusion following high-pressure intraoronary stenting. Am. J. Cardiol. 1997; 80: 994-997.

14.      Sheiban I. et al. Immediate and long-term results of «T» stenting for bifurcation coronary lesions. Am. J. Сardiol. 2000; 85: 1141-1144.

15.      Louvard Y., Lefevre T., Morice M.C. Percutaneous coronary intervention for bifurcation coronary disease. Heart. 2004; 90: 713-722.

16.      Tanabe K. et al. Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narro wings. Am.J. Cardiol. 2004; 94: 115-118.

17.      Colombo A. et al. The modified «T» stenting technique with «crushing» for bifurcation lesions: Immediate results and 30-day outcome. Catheter Cardiovasc. Interv. 2003; 60: 145-151.

18.      Suwaidi A.J. et al. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J. Am. Coll. Cardiol. 2000; 35: 929-936.

19.      Yamashita T. et al. Bifurcation lesions: two stents versus one stent-immediate and follow-up results. J. Am. Coll. Cardiol. 2000; 35: 1145-1151. Steigen T.K. et al. Randomise study on simple